SK Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

SK Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$486K	Hold	927	–	–	0.11%	54
2026 Q1	$403K	Hold	927	–	–	0.11%	54
2025 Q4	$441K	Hold	927	–	–	0.12%	55
2025 Q3	$385K	Hold	927	–	–	0.14%	61
2025 Q2	$444K	Sell	927 -530	-36%	-$244K	0.19%	51
2025 Q1	$696K	Hold	1,457	–	–	0.37%	40
2024 Q4	$587K	Hold	1,457	–	–	0.3%	42
2024 Q3	$596K	Buy	+1,457	New	+$700K	0.3%	42

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

SK Wealth Management's VRTX Position: Q2 2026 in Review

SK Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 927 shares worth $486K. The position accounts for 0.11% of the portfolio, ranked #54.

SK Wealth Management first reported a position in VRTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $696K in Q1 2025. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

SK Wealth Management held 927 shares of Vertex Pharmaceuticals worth $486K as of Q2 2026.
SK Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.11% of SK Wealth Management's portfolio in Q2 2026, its #54 holding.
SK Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
SK Wealth Management's Vertex Pharmaceuticals position peaked at $696K in Q1 2025.
1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on SK Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.